Circulating anti-Mullerian hormone carries increased breast cancer risk

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Circulating anti-Müllerian hormone (AMH) is linked to elevated breast cancer risk, with a 60% increase for women in the top vs bottom quartile of AMH.

Why this matters

  • AMH has the potential to be one of the few breast cancer biomarkers.

Study design

  • A nested case-control design (n=3122 breast cancers) was conducted across 10 prospective cohorts.
  • AMH was assessed by high-sensitivity enzyme-linked immunoabsorbent assay.
  • Funding: NIH to Sister Study; Avon Foundation for Women.

Key findings

  • There was a 60% increase in odds of breast cancer for women in the top quartile of AMH vs the bottom AMH quartile (OR, 1.60; 95% CI, 1.31-1.94).
  • The trend was significant only for tumors that were positive for both estrogen receptor and progesterone receptor in the top vs bottom AMH quartile (OR, 1.96; 95% CI, 1.46-2.64).
  • The association between AMH and breast cancer applied to both premenopausal (OR, 1.35; 95% CI, 1.05-1.73) and postmenopausal (OR, 1.61; 95% CI, 1.03-2.53) breast cancer.

Limitations

  • Relatively small sample size.